Infant Phototherapy Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The infant phototherapy devices market size is projected to be USD 261.39 million in 2025, USD 271.71 million in 2026, and reach USD 329.79 million by 2031, growing at a CAGR of 3.95% from 2026 to 2031. This report is segmented by Light Source (Fluorescent Lamps, Light-Emitting Diodes, Quartz Halogen Lamps, Gas Discharge Tubes), Care Setting (Hospitals and NICUs, Neonatal Clinics, Homecare, Others), Treatment Intensity (Standard, Intensive, Combined), Clinical Use (Physiological Jaundice and More), and Geography (North America and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Infant Phototherapy Devices Market Trends and Insights

High Incidence of Neonatal Jaundice Sustains Device Demand

Neonatal jaundice affects 60% of term newborns and up to 80% of preterm infants globally during the first week of life. This clinical burden keeps phototherapy relevant across neonatal settings and provides the infant phototherapy devices market with a sustained treatment base. An estimated 10% of neonates require active phototherapy, which equates to 13-14 million infants each year based on WHO live-birth estimates. Severe neonatal jaundice among hospital admissions ranges from 0.73% to 3.34% across WHO regions, with the highest incidence reported in African and South-East Asian regions. The geographic pattern places greater weight on device affordability and dependable supply in these settings. It also supports demand for equipment that can perform reliably where clinical resources are constrained.

Rising Preterm and Low-Birth-Weight Deliveries Widen the Clinical Indication Base

Preterm and low-birth-weight infants have a higher risk of severe hyperbilirubinemia, expanding the number of newborns that may need phototherapy. This risk profile matters for the infant phototherapy devices market because preterm newborns often need longer treatment and stronger irradiance. They may also require double-surface treatment, increasing device use for each episode of care. A 2026 network meta-analysis found that double-surface phototherapy in preterm infants achieved higher total serum bilirubin reduction than single-surface treatment. This evidence supports the demand for systems that combine overhead light with a fiber-optic blanket. It also favors designs that can be used safely around medically fragile infants in incubators within the infant phototherapy devices market.

High Upfront Cost of Advanced Devices Constrains Emerging-Market Procurement

Advanced LED systems can strain public procurement budgets in emerging markets. Double-surface units and systems with integrated monitoring have higher acquisition requirements than basic overhead equipment. Hospitals in South Asia and sub-Saharan Africa may continue using single fluorescent units when capital budgets are limited. This can reduce irradiance performance and leave clinical needs less fully addressed. Total ownership costs also include irradiance measurement tools, eye protection supplies, and replacement lamps for non-LED equipment. Manufacturers in the infant phototherapy devices market are responding with modular and battery-compatible systems, but tender-based buying processes can extend sales cycles and limit margins.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Neonatal Intensive Care Capacity Unlocks Capital Equipment Procurement
• LED Technology Displacement Reshapes Device Economics
• Monitoring Requirements Create a Dual Infrastructure Burden

Segment Analysis

Light-emitting diodes held 48.31% of the light-source segment in 2025 and are forecast to expand at a 5.65% CAGR through 2031. LED systems work within the 450-475 nm range that aligns with bilirubin absorption requirements. Modern units achieved bilirubin reductions of 28-43% within 48-96 hours in a 2025 study. They also generated less heat and fewer adverse events than fluorescent alternatives in the reported comparison. The infant phototherapy devices industry is placing more value on energy efficiency, lamp durability, and consistent light output.

Fluorescent lamps retained an installed base in lower-resource settings where the initial price remains important. Their shorter operating life creates recurring maintenance requirements compared with LED equipment. Quartz-halogen lamps are declining because high heat can increase insensible water loss in newborns. Gas discharge tubes retain a narrower role in specialized combined systems. IEC 62471 safety requirements and clinical irradiance guidance increasingly support LED-centered designs in the infant phototherapy devices market.

Hospitals and NICUs represented 75.24% of the infant phototherapy devices market size by care setting in 2025. Institutional care can provide irradiance monitoring, serum bilirubin testing, and continuous nursing oversight. These capabilities remain necessary for newborns with neurotoxicity risk factors. The American Academy of Pediatrics identifies preterm infants below 38 weeks of gestation and newborns with hemolytic disease as patients requiring careful management. Ongoing NICU projects in North America and Asia-Pacific will continue to support institutional procurement through 2031.

Homecare settings are forecast to grow at a 5.22% CAGR from 2026 to 2031. Structured programs allow suitable low-risk term newborns to receive treatment outside an inpatient bed. A 2026 systematic review found comparable total serum bilirubin reduction for selected home and in-hospital patients. It also reported a 3.5% readmission rate and 70% lower cost for home phototherapy in structured hospital-at-home programs. Singapore’s KKH@Home program recruited 134 patients from April through December 2024 and saved 200 inpatient bed-days, reinforcing the role of compact fiber-optic, portable, and wearable equipment in the infant phototherapy devices market.

Complete Report Scope:

• By Light Source
  • Fluorescent Lamps
  • Light-Emitting Diodes
  • Quartz Halogen Lamps
  • Gas Discharge Tubes
• By Care Setting
  • Hospitals and Neonatal Intensive Care Units
  • Neonatal Clinics and Maternity Centers
  • Homecare Settings
  • Other Care Settings
• By Treatment Intensity
  • Standard-Intensity Phototherapy
  • Intensive Phototherapy
  • Combined Overhead and Fiber-Optic Phototherapy
• By Clinical Use
  • Physiological Jaundice
  • Breast Milk Jaundice
  • Jaundice in Preterm Infants
  • Other Clinical Uses
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 36.61% of the regional share in 2025. The region benefits from extensive NICU infrastructure and strong procurement of higher-specification equipment. Texas Children’s announced its USD 39 million Austin expansion in August 2026, with room capacity set to rise from 14 to 31. The project is expected to serve up to 300 additional patient episodes annually when completed in fall 2027. These expansions create continuing purchase needs for phototherapy systems and related monitoring equipment in the infant phototherapy devices market.

Europe held the second-largest geographic share in 2025. Germany, the United Kingdom, and France account for a significant portion of regional revenue. German practice uses age-stratified bilirubin thresholds, including a 20 mg/dL trigger for healthy term infants aged 72 hours or more. German neonatal units have adopted LED systems at a high rate because of strict photobiological safety expectations. Universitätsmedizin Halle tested a phototherapy sleeping-bag system that supports breastfeeding and skin-to-skin contact during treatment.

Asia-Pacific is the fastest-growing regional area at a 5.65% CAGR from 2026 to 2031. China’s NICU capacity expanded by 7-8% annually from 2020 to 2025 under Healthy China 2030, supporting domestic equipment demand. The installed base of phototherapy machines in China is projected to exceed 200,000 units by 2030. India’s increasing institutional deliveries and neonatal screening requirements also support regional demand in the infant phototherapy devices market.

List of Companies Covered in this Report:

• Atom Medical
• BabyBloom Healthcare B.V.
• Bistos Co., Ltd.
• BPL Medical Technologies Pvt. Ltd.
• Dragerwerk
• Fanem Ltda
• GE Healthcare
• Heal Force Bio-Meditech Holdings Limited
• Ibis Medical Equipment and Systems Pvt. Ltd.
• Koninklijke Philips
• Natus Medical
• NeoLight LLC
• NeoMedLight
• Nice Neotech Medical Systems Pvt. Ltd.
• Ningbo David Medical Device
• Phoenix Medical Systems
• Shenzhen Comen Medical Instruments Co., Ltd.
• Zhengzhou Dison Instrument and Meter Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support